Feeling better with MorphiDex

In developing drugs for subjective indications such as pain, a challenge is finding objective end points that measure efficacy rather than patient feelings and placebo effects.

Last week Algos Pharmaceutical Corp. announced data from an open-label Phase III trial in chronic pain showing that 88 percent of the 250 patients treated with the company's MorphiDex rated the agent as good, very good, or excellent two weeks after switching from morphine, fentanyl or